Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise
SR Gameiro, ML Jammeh, JW Hodge - Expert review of vaccines, 2013 - Taylor & Francis
Concurrent with the US FDA's approval of the first therapeutic cancer vaccine, and
supported by mounting clinical evidence indicating that targeting carcinoembryonic antigen …
supported by mounting clinical evidence indicating that targeting carcinoembryonic antigen …
Strategies for cancer therapy using carcinoembryonic antigen vaccines
HL Kaufman, H Hörig, FA Medina, S Golding… - Expert reviews in …, 2000 - cambridge.org
Advances in molecular biology and immunology have renewed interest in the development
of vaccines for the treatment or prevention of cancer. Research over the past 10 years has …
of vaccines for the treatment or prevention of cancer. Research over the past 10 years has …
Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review
NL Berinstein - Journal of Clinical Oncology, 2002 - ascopubs.org
PURPOSE: To describe the features of carcinoembryonic antigen (CEA) that are important
for its use in vaccination approaches and review the clinical experience with therapeutic …
for its use in vaccination approaches and review the clinical experience with therapeutic …
Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials
M Turriziani, M Fantini, M Benvenuto… - Recent patents on …, 2012 - ingentaconnect.com
Carcinoembryonic antigen (CEA), a glycosylated protein of MW 180 kDa, is overexpressed
in a wide range of human carcinomas, including colorectal, gastric, pancreatic, non-small …
in a wide range of human carcinomas, including colorectal, gastric, pancreatic, non-small …
CEA-based vaccines
EH Huang, HL Kaufman - Expert review of vaccines, 2002 - Taylor & Francis
Carcinoembryonic antigen (CEA), the first tumor-associated antigen to be described, was
cloned in 1987 and is expressed on nearly 50% of all human tumors. The identification of T …
cloned in 1987 and is expressed on nearly 50% of all human tumors. The identification of T …
[HTML][HTML] Recombinant AAV-CEA tumor vaccine in combination with an immune adjuvant breaks tolerance and provides protective immunity
JA Hensel, V Khattar, S Ponnazhagan - Molecular Therapy-Oncolytics, 2019 - cell.com
Carcinoembryonic antigen (CEA) is a human glycoprotein involved in cellular adhesion and
expressed during human fetal development. Although expression of CEA largely ceases …
expressed during human fetal development. Although expression of CEA largely ceases …
Carcinoembryonic antigen-based vaccines
J Marshall - Seminars in oncology, 2003 - Elsevier
Carcinoembryonic antigen (CEA) is a glycoprotein that is normally expressed in certain parts
of the body and commonly overexpressed in most carcinomas of the colon, rectum, breast …
of the body and commonly overexpressed in most carcinomas of the colon, rectum, breast …
A novel CEA vaccine stimulates T cell proliferation, γIFN secretion and CEA specific CTL responses
T Parsons, I Spendlove, R Nirula, M Writer, G Carter… - Vaccine, 2004 - Elsevier
Carcinoembryonic antigen (CEA) is a cell surface protein over-expressed by a wide range of
tumours. The mouse anti-idiotypic antibody, 708, mimics CEA and can induce both antibody …
tumours. The mouse anti-idiotypic antibody, 708, mimics CEA and can induce both antibody …
Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice
R Xiang, S Silletti, HN Lode, CS Dolman… - Clinical cancer …, 2001 - AACR
Peripheral T-cell tolerance toward human carcinoembryonic self-antigen (CEA) was broken
in CEA-transgenic C57BL/6J mice by an oral CEA-based DNA vaccine. This vaccine …
in CEA-transgenic C57BL/6J mice by an oral CEA-based DNA vaccine. This vaccine …